Associated Papers
RAS and BRAF mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-tested RAS wild-type advanced colorectal cancer.
van Helden EJ et al.
Molecular Oncology, 2019
31350822 (PubMed )
Supplement: MOL2-13-2361-s007.xlsx › Blad1
Co-occurring Genomic Alterations and Association With Progression-Free Survival in BRAFV600-Mutated Nonmelanoma Tumors.
Sen S et al.
Journal of the National Cancer Institute, 2017
Select a paper to view details